Of the thyroid cancers, p53 inactivation is particularly common in PDTCs and ATCs, with a prevalence of 8–35% in PDTCs and significantly higher prevalence of up to 73% in ATCs, especially in association with BRAFV600E mutation [17,19,20]. The gene discussed is TP53; the disease is Ehlers-Danlos syndrome, musculocontractural type.